Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ELAD

ELAD

Liraglutide · Mild cognitive impairment + T2D

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Liraglutide
Population
Mild cognitive impairment + T2D
Participants
396
Duration
48 weeks

Outcomes in the indication

ELAD Liraglutide · Mild cognitive impairment + T2D · 48 weeks · n = 396 congress

MCI reversal 49.5 % vs 20.4 % on linagliptin (EASD 2026)

MeasureDrugControlDifference (95 % CI)Status
Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline
week 52
——−0.2 (−0.4 to +0.1) FDG-PET SUVverified
Verbatim quotes (1)
  • Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline
    The primary outcome showed no significant differences in cerebral glucose metabolism (difference = -0.17; 95% confidence interval: -0.39 to 0.06; P = 0.14) between the two groups.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ELAD. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/elad/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.